Industry news

• Amendments to drug registration law in Russia: Implications for the future

  26 March 2013 Kavita Rainova, IHS Healthcare and Pharma blog

  The eagerly awaited draft amendments to the federal law, as well as Article 333.32.1, part two of the tax code of the Russian Federation, were published for consultation by the country’s Ministry of Health in late January this year. The amendments proved to be a mixed bag.

• Expert team publishes International Declaration after Open Innovations International Forum

  22 March 2013

  The panel consisting of the well-known venture capitalists, managers of the world-leading universities, market analysts, and representatives of Russian development institutes prepared the International Declaration on the Forum "Open Innovation 2012".

• Can Russia repeat last year’s GDP growth?

  18 March 2013 Viktor Kuzmin, Russia Beyond The Headlines

  Russia led the G-8 and ranked second among BRICS countries in terms of economic growth rates in 2012. Experts make guesses whether Moscow will be able to replicate its performance in 2013.

• Health Ministry Proposes Drug Registration System

  17 March 2013 The Moscow Times

  The Health Ministry wants to create a database for controlling medicine sold in drug stores across the country.

• Ukrainian government to simplify procedure for registration of imported drugs

  17 March 2013 The Pharma Letter

  The government of Ukraine plans to simplify the procedure of registration of drugs, imported to the country from the European Union. According to an official representative of the Ukrainian State Drugs Service, all the companies, whose drugs are registered by the European Medicines Agency will pass the procedure for their registration in Ukraine only by filing a single application to the country’s Ministry of Health.

• Science and Technology cooperation to grow between India and Russia

  15 March 2013 Russia & India Report

  There is a gamut of bilateral links and inter-governmental mechanisms in diverse science and technology sectors beyond defence and nuclear power.

• Biologics Research Promises to Bolster the Future of Medicine

  14 March 2013 The Pharmaceutical Research and Manufacturers of America (PhRMA)

  America’s biopharmaceutical research companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases. Many biologics are made from a variety of natural sources—human, animal or microorganisms. Like small-molecule drugs, some biologics are intended to treat diseases and medical conditions. Other biologics are used to prevent or diagnose disease.

• America’s biopharmaceutical research companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases

  14 March 2013 The Pharmaceutical Research and Manufacturers of America (PhRMA)

  America’s biopharmaceutical research companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report from PhRMA. The medicines and vaccines – all in human clinical trials or under review the U.S. Food and Drug Administration (FDA) – include 338 monoclonal antibodies, 250 vaccines, 93 recombinant proteins, 60 cell therapies, 46 gene therapies and 30 antisense medicines.  

• RUSNANO invests $825 000 in Bioptix Company

  14 March 2013 venture-news.ru

  RUSNANO, JSC will invest $825 000 in Bioptix Diagnostics, Inc within the next funding round. According to the press service of the nanotech company, this decision was made by RUSNANO's board of directors. Bioptix Diagnostics, Inc. plans to invest the funds raised in further development of label-free bio-detectors of second generation, and start their sales. 

• 'Pharma Clinical Trial Services Market Will Reach $30.6 Billion in 2015' Predicts New Visiongain Report

  04 February 2013

  A new report by Visiongain predicts that the world market for pharma clinical trial services will be worth $30.6bn in 2015. Between 2011 and 2017, the global market will grow with a high single digit CAGR. Demand for late phase trial services will drive growth to 2023. Those findings appear in Pharma Clinical Trial Services: World Market 2013-2023, published in January 2013. Growth for these CROs will be focused on building upon the service portfolio in these markets, as well as entering new emerging markets in Asia, Latin America and Central and Eastern Europe.